Provided by Tiger Trade Technology Pte. Ltd.

Milestone Pharmaceuticals Inc.

1.04
-0.1100-9.57%
Post-market: 1.040.00000.00%19:51 EDT
Volume:2.94M
Turnover:3.18M
Market Cap:122.72M
PE:-1.38
High:1.15
Open:1.15
Low:1.03
Close:1.15
52wk High:3.06
52wk Low:0.6254
Shares:118.00M
Float Shares:67.59M
Volume Ratio:0.85
T/O Rate:4.35%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.7517
EPS(LYR):-0.6674
ROE:-229.65%
ROA:-41.08%
PB:2.94
PE(LYR):-1.56

Loading ...

Milestone Pharmaceuticals files Form 3 for GC and Chief Compliance Officer David I. Sandoval

Reuters
·
Mar 24

Regulatory Disruptions Pose Material Operational Risks for Milestone Pharmaceuticals

TIPRANKS
·
Mar 21

Why Milestone Pharma Stock Is Taking A Dive Today

Benzinga
·
Mar 20

Milestone Pharmaceuticals Q4 EPS $(0.16), Inline, Sales $1.546M Beat $1.200M Estimate

Benzinga
·
Mar 20

Milestone Pharmaceuticals Inc - Q4 2025 Net Loss Was $17.4 Mln or $0.16 per Share

THOMSON REUTERS
·
Mar 20

Milestone Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Update on the Commercial Launch of Cardamyst™ (Etripamil) Nasal Spray for the Treatment of Psvt

THOMSON REUTERS
·
Mar 20

Press Release: Milestone Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Update on the Commercial Launch of CARDAMYST(TM) (etripamil) Nasal Spray for the Treatment of PSVT

Dow Jones
·
Mar 20

Milestone Pharmaceuticals FY2025 net loss widens 51.9% to USD 63.06 million, commercial expenses more than doubled to USD 28.3 million

Reuters
·
Mar 20

Milestone Pharmaceuticals Gears Up For Q4 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts

Benzinga
·
Mar 20

Milestone Pharmaceuticals Inc expected to post a loss of 16 cents a share - Earnings Preview

Reuters
·
Mar 18

Milestone Pharmaceuticals to present CARDAMYST nasal spray data and host an expert theater at ACC.26

Reuters
·
Mar 16

Milestone Pharmaceuticals to Report Q4 and Full-Year 2025 Financial Results and Host Investor Call

Reuters
·
Mar 12

Milestone Pharmaceuticals Inc expected to post a loss of 16 cents a share - Earnings Preview

Reuters
·
Mar 09

Press Release: Milestone Pharmaceuticals Appoints David Sandoval as General Counsel and Chief Compliance Officer

Dow Jones
·
Feb 10

Milestone Pharmaceuticals Chief Medical Officer David Bharucha Reports Disposal of Common Shares

Reuters
·
Jan 29

Milestone Pharmaceuticals Inc - National Sales Force Deployment for Cardamyst Set for Mid-February 2026

THOMSON REUTERS
·
Jan 26

Milestone Pharmaceuticals Announces U.S. Availability of Cardamyst™ (Etripamil) Nasal Spray, the First and Only FDA-Approved Self-Administered Treatment for Adults With Paroxysmal Supraventricular Tachycardia (Psvt)

THOMSON REUTERS
·
Jan 26

Milestone Pharmaceuticals Inc - Copays for Eligible Insured Patients Expected to Be Capped at $25

THOMSON REUTERS
·
Jan 26

Milestone Pharmaceuticals CEO Joseph Oliveto Reports Disposal of Common Shares

Reuters
·
Jan 10

Milestone Pharmaceuticals Price Target Maintained With a $8.00/Share by HC Wainwright & Co.

Dow Jones
·
Jan 07